Initial $50M Series A investment from founding investor RTW InvestmentsProceeds will fund clinical development of PRO-203 in systemic sclerosis ...

London, UK – 3 March, 2026 – Quell Therapeutics Ltd (“Quell”), today announced that it has initiated a Phase 1/2 basket clinical study evaluating ...

A retrospective cohort study found that beta-blocker use is associated with a decreased risk for incident HF in certain SAID populations.

Quell Therapeutics has begun its chill phase 1/2 clinical trial evaluating QEL‑005, an autologous CAR‑Treg therapy designed for people with rheumatoid arthritis and systemic sclerosis. The move ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Proximal weakness and elevated creatine kinase were ...

Systemic sclerosis is a complex autoimmune condition marked by aberrant immune activation, widespread fibrosis and vasculopathy that affect the skin and multiple internal organs. The disease manifests ...

Preclinical data showed promise in both systemic sclerosis bleomycin-induced mouse models and in patient-derived skin fibroblasts treated with EYD-001. The Food and Drug Administration (FDA) has ...

Please provide your email address to receive an email when new articles are posted on . Nearly 10% of patients with systemic sclerosis had systemic sclerosis sine scleroderma, a subtype without skin ...

A nationwide Swedish register-based study revealed that individuals with systemic sclerosis had a higher risk for hematologic malignancies. Myeloid malignancies typically presented around disease ...

New research at ACR Convergence 2023, the American College of Rheumatology's (ACR) annual meeting, shows that patients with refractory juvenile systemic sclerosis improved significantly on nearly all ...

Although less common than other subtypes of systemic sclerosis (SSc), systemic sclerosis sine scleroderma (ssSSc) makes up more than 8% of SSc cases and "should not be neglected," according to a new ...